Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Mok · SciRah

Researcher profile · Semantic Scholar

T. Mok

Share profile

T. Mok — researcher profile on SciRah

h-index: 101
Works: 598
Citations: 63K

Most-cited papers

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
A. Shaw, T. Bauer, F. de Marinis, E. Felip +10 more
2020New England Journal of Medicine859 citations Open access
Semantic Scholar
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
L. Hendriks, K. Kerr, J. Menis, T. Mok +8 more
2023Annals of Oncology805 citations Open access
Semantic Scholar
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.
L. Hendriks, K. Kerr, J. Menis, T. Mok +8 more
2023Annals of Oncology574 citations Open access
Semantic Scholar
Overcoming therapy resistance in EGFR-mutant lung cancer
A. Passaro, P. Jänne, T. Mok, S. Peters
2021Nature Cancer508 citations
Semantic Scholar
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
N. Nogami, F. Barlesi, M. Socinski, M. Reck +19 more
2021Journal of Thoracic Oncology285 citations Open access
Semantic Scholar
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
G. de Castro, I. Kudaba, Yi-Long Wu, G. Lopes +14 more
2022Journal of Clinical Oncology257 citations Open access
Semantic Scholar
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
V. Papadimitrakopoulou, T. Mok, Jy Han, M.-J. Ahn +16 more
2020Annals of Oncology241 citations Open access
Semantic Scholar
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
L. Horn, Zi-Ping Wang, Gang Wu, E. Poddubskaya +19 more
2021JAMA Oncology238 citations Open access
Semantic Scholar
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
B. Solomon, T. Bauer, T. Mok, Geoffrey Liu +14 more
2022The Lancet Respiratory Medicine188 citations
Semantic Scholar
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Sehhoon Park, C. Ock, Hyojin Kim, Sérgio Pereira +25 more
2022Journal of Clinical Oncology184 citations Open access
Semantic Scholar
Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations.
A. Passaro, T. Mok, S. Peters, S. Popat +2 more
2020Journal of Thoracic Oncology161 citations Open access
Semantic Scholar
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
M. Socinski, R. Jotte, F. Cappuzzo, M. Nishio +8 more
2023JAMA Oncology154 citations Open access
Semantic Scholar
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
T. Mok, Ying Cheng, Xiang-Dong Zhou, K. Lee +12 more
2020Drugs107 citations Open access
Semantic Scholar
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer
A. Schoenfeld, S. Antonia, M. Awad, E. Felip +14 more
2021Annals of Oncology89 citations Open access
Semantic Scholar
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study
Yi-Long Wu, Li Zhang, Yun Fan, Jian-Ying Zhou +12 more
2020International Journal of Cancer89 citations Open access
Semantic Scholar
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
A. Mansfield, R. Herbst, G. de Castro, R. Hui +13 more
2021JTO Clinical and Research Reports81 citations Open access
Semantic Scholar
Transbronchial microwave ablation of lung nodules with electromagnetic navigation bronchoscopy guidance—a novel technique and initial experience with 30 cases
J. Chan, R. Lau, J. Ngai, C. Tsoi +3 more
2021Translational Lung Cancer Research80 citations Open access
Semantic Scholar
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC.
T. Mok, G. Lopes, B. Cho, D. Kowalski +13 more
2023Annals of Oncology71 citations Open access
Semantic Scholar
Testing for COVID-19 in lung cancer patients
A. Passaro, Solange Peters, T. Mok, I. Attili +2 more
2020Annals of Oncology66 citations Open access
Semantic Scholar
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
O. Chan, K. Lam, J. Li, F. Choi +6 more
2020Lung Cancer65 citations
Semantic Scholar
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Shun Lu, Jie Wang, Ying Cheng, T. Mok +20 more
2020Lung Cancer63 citations Open access
Semantic Scholar
Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Molly S. C. Li, Kevin K. S. Mok, T. Mok
2023Annals of Translational Medicine60 citations Open access
Semantic Scholar
Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Sangjoon Choi, S. Cho, M. Ma, Seonwook Park +13 more
2022European Journal of Cancer54 citations
Semantic Scholar
Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
R. Dziadziuszko, T. Mok, S. Peters, Ji-Youn Han +21 more
2021Journal of Thoracic Oncology50 citations Open access
Semantic Scholar
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
M. Johnson, B. Cho, A. Luft, J. Alatorre-alexander +17 more
2021Journal of Thoracic Oncology49 citations Open access
Semantic Scholar
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
Timothy F. Burns, H. Borghaei, S. Ramalingam, T. Mok +1 more
2020Journal of Clinical Oncology49 citations Open access
Semantic Scholar
Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection
G. Wong, V. Wong, V. W. Hui, T. Yip +6 more
2021American Journal of Gastroenterology46 citations
Semantic Scholar
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
Guo-Fu Lin, Chao Li, P.-S. Li, W. Fang +28 more
2020Annals of Oncology46 citations Open access
Semantic Scholar
LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
T. Mok, K. Nakagawa, K. Park, Y. Ohe +16 more
2022Annals of Oncology45 citations Open access
Semantic Scholar
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
S. Chan, Paul N. M. Cheng, Angela M. Liu, L. Chan +9 more
2021Investigational new drugs45 citations Open access
Semantic Scholar
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Ying Cheng, T. Mok, Xiang-Dong Zhou, Shun Lu +16 more
2021Lung Cancer42 citations Open access
Semantic Scholar
ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3
G. Selvaggi, H. Wakelee, T. Mok, Y.-L. Wu +17 more
202042 citations Open access
Semantic Scholar
Distinct Molecular Landscape of Epstein–Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing
S. Chau, J. Tong, Chit Chow, J. S. Kwan +10 more
2020Cancers39 citations Open access
Semantic Scholar
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
A. Passaro, T. Mok, I. Attili, Yi-Long Wu +3 more
2023JAMA Oncology38 citations
Semantic Scholar
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
R. Dziadziuszko, S. Peters, T. Mok, D. Camidge +9 more
2022Clinical Cancer Research36 citations Open access
Semantic Scholar
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
T. Mok, S. Peters, D. Camidge, J. Noé +9 more
2020Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.
T. Mok, W. Lawler, M. Shum, S. Dakhil +10 more
2021Journal of Clinical Oncology27 citations
Semantic Scholar
FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
B. Cho, Y.-L. Wu, G. Lopes, I. Kudaba +14 more
202126 citations Open access
Semantic Scholar
International expert consensus on immunotherapy for early-stage non-small cell lung cancer
W. Liang, K. Cai, Q. Cao, Chun Chen +80 more
2022Translational Lung Cancer Research25 citations Open access
Semantic Scholar
1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
M. Reck, T. Mok, M. Socinski, R. Jotte +14 more
202023 citations Open access
Semantic Scholar
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
S. Peters, T. Mok, S. Gadgeel, R. Rosell +11 more
202023 citations
Semantic Scholar
Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.
M. Reck, T. Mok, A. Mansfield, R. De Boer +13 more
2022Journal of Thoracic Oncology22 citations Open access
Semantic Scholar
Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now?
J. Chan, Ivanov SIu, A. Chang, Molly S. C. Li +3 more
2023Cancers20 citations Open access
Semantic Scholar
Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
M. Socinski, R. Jotte, F. Cappuzzo, M. Nishio +8 more
2021Journal of Clinical Oncology20 citations
Semantic Scholar
LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
T. Mok, J. Pujol, M. Tsuboi, J. Lee +8 more
2022Annals of Oncology17 citations Open access
Semantic Scholar
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-free DNA in Patients With Non-Small Cell Lung Cancer.
K. Lee, Molly S. C. Li, Wan-Xia Gai, Y. Lau +10 more
2022JAMA Oncology17 citations Open access
Semantic Scholar
1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
Stephen V. Liu, L. Horn, T. Mok, A. Mansfield +13 more
2020Annals of Oncology16 citations Open access
Semantic Scholar
OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
D. Rodríguez-Abreu, Y.-L. Wu, M. Boyer, M. Garassino +18 more
2022Journal of Thoracic Oncology15 citations Open access
Semantic Scholar
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
R. Dziadziuszko, S. Peters, S. Gadgeel, M. Mathisen +16 more
2021Annals of Oncology15 citations Open access
Semantic Scholar
The Promising Evolution of Targeted Therapeutic Strategies in Cancer.
S. Peters, T. Mok, A. Passaro, P. Jänne
2021Cancer Discovery14 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Reck×14
Invite
M. Reck — researcher profile on SciRah
S. Peters×10
Invite
S. Peters — researcher profile on SciRah
A. Passaro×8
Invite
A. Passaro — researcher profile on SciRah
Yi-Long Wu×7
Invite
Yi-Long Wu — researcher profile on SciRah

×6

Invite

F. de Marinis — researcher profile on SciRah

Invite

Y.-L. Wu — researcher profile on SciRah

R. Dziadziuszko×6

Invite

R. Dziadziuszko — researcher profile on SciRah

Dong-Wan Kim×5

Invite

Dong-Wan Kim — researcher profile on SciRah

Invite

B. Solomon — researcher profile on SciRah

G. de Castro×5

Invite

G. de Castro — researcher profile on SciRah

Invite

A. Shaw — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah